Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Shares Outstanding (Weighted Average) (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 18.37% year-over-year to $3.0 million; the TTM value through Sep 2025 reached $3.0 million, up 18.37%, while the annual FY2024 figure was $2.5 million, 7.7% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $3.0 million in Q3 2025 for Cyclerion Therapeutics, down from $3.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $43.3 million in Q3 2021 and bottomed at $43425.0 in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $9.8 million, with a median of $2.5 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) tumbled 99.87% in 2022 and then skyrocketed 4910.94% in 2023.
  • Cyclerion Therapeutics' Shares Outstanding (Weighted Average) stood at $39.1 million in 2021, then tumbled by 94.45% to $2.2 million in 2022, then rose by 7.59% to $2.3 million in 2023, then rose by 7.7% to $2.5 million in 2024, then increased by 17.99% to $3.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $3.0 million, $3.1 million, and $2.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.